El European Innovation Council (EIC) Fund i Methinks AI, empresa de salut digital especialitzada en la detecció precoç i el maneig de pacients amb ictus agut mitjançant intel·ligència artificial (IA), anuncien una important inversió de l’EIC Fund, a la qual s’hi afegeix la participació d’inversors existents i la incorporació d’un nou inversor. En total, Methinks AI, que és membre de CataloniaBio & HealthTech, ha captat 2,5 milions d’euros en préstecs convertibles amb l’objectiu de preparar la seva propera ronda d’inversió.

Oxolife, member of CataloniaBio & HealthTech, announces it has appointed globally renowned fertility experts to its Scientific Advisory Board (SAB).  

Mitelos, member of CataloniaBio & HealthTech, announced a significant milestone: the sale of 3 million units of their ear care products. This achievement highlights their unwavering dedication to delivering quality ear care solutions and underscores the trust their customers have placed in us.  

Inbiomotion SL, member of CataloniaBio & HealthTech and a company in the portfolio of Ysios Capital (member too), has announced the publication in Nature Cell Biology of key data further elucidating the biology around the MAF biomarker. 

CataloniaBio & HealthTech, as an AEI (Innovative Business Group, in Spanish) recognised by the Ministry of Industry, Trade and Tourism (Mincotur) has participated for the first time in the calls for aid that they promote. These industrial research calls are aimed at incorporating knowledge and technologies that promote the digital transformation of companies. This is the first time it has been eligible since it was accepted onto the register in the summer of 2022.

Asabys Partners, member of CataloniaBio & HealthTech, along with companies such as Novator Partners, Frumtak Ventures, and Wellington Partners, are prominent investors in Sidekick Health. Asabys participated in the $55 million funding round in May 2022, which laid the foundation for the company to continue growing and innovating, generating a greater impact in the digital health and therapeutic sectors.  

Vytrus Biotech, member of CataloniaBio & HealthTech, has received €575,000 in financing from the Center for Technological Development and Innovation (CDTI), affiliated with the Ministry of Science and Innovation of the Spanish Government, for the development of cutting-edge technologies in the field of dermocosmetics and health.  

Cebiotex, member of CataloniaBio & HealthTech, is working on a drug that consists of a membrane made from biodegradable fibers that releases a natural molecule with a high chemotherapeutic capacity and can be implanted after tumor extraction, on the surgical bed. It can be used in the treatment of localized solid tumours. 

Reig Jofre, member of CataloniaBio & HealthTech, has achieved significant success together with their partner Maruishi Pharmaceutical in Japan. They have produced in Barcelona and marketed in Japan 15 million vials of Remifentanil, a state-of-the-art intravenous anesthetic for hospital use. This product, internally developed by the company, is manufactured at Reig Jofre's sterile injectables and lyophilized plant. 

Ysios Capital, a member of CataloniaBio & HealthTech, has announced its participation in the financing round of the company Kynexis (Naarden, Netherlands) for a total amount of 57 million euros. The company, co-founded by Ysios Capital and Forbion, has an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation to develop and market the product KYN5356 worldwide.

Oryzon Genomics, member of CataloniaBio & HealthTech, has announced that it is developing a new molecule for the treatment of personality disorders. This new molecule, called ORY-304, acts as a selective inhibitor of LSD1, an enzyme involved in the epigenetic regulation of genes related to behaviour and emotions. Personality disorders are a group of mental disorders that affect how people perceive, think, and relate to others. These disorders are difficult to treat and have a significant impact on the quality of life of those affected. 

Gate2Brain, member of CataloniaBio & HealthTech, has announced that it has received funding from EIT Health, a European health innovation network. This investment will allow Gate2Brain to advance the development of its revolutionary technology for drug administration to the brain. 

Sant Joan de Deu Hospital, member of CataloniaBio & HealthTech, and Microsoft have announced a strategic collaboration for the creation of an Artificial Intelligence (AI) laboratory aimed at developing digital health projects. This initiative aims to promote innovation in the field of health through the application of advanced technologies. 

Peptomyc, member of CataloniaBio & HealthTech, announced today that it has received a €5 million grant from the EIC (European Innovation Council) acceleration program of Horizon Europe. This funding will allow Peptomyc to carry out a phase 1b clinical trial with its drug candidate OMO-103 in patients, as well as scale up its manufacturing process. 

At the Germans Trias i Pujol Research Institute (IGTP), member of CataloniaBio & HealthTech, the day "Translational research and innovation through EATRIS" was held. The purpose of this event was to discuss the progress and perspectives of EATRIS both in Spain and in Europe, and to highlight the research and innovation activity of the IGTP. 

Anaxomics, member of CataloniaBio & HealthTech, is at the forefront of an innovative project aimed at analysing the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Under the name Project Mathrix, this study, in collaboration with Takeda and a multidisciplinary team of experts, uses virtual patient simulations and Artificial Intelligence techniques to deepen the understanding of ADHD treatments. 

The biotechnology company GoodGut, a member of CataloniaBio & HealthTech, in collaboration with the Galician Department of Health, has initiated a pilot study of an innovative test based on quantitative PCR techniques. This test is intended to assess its potential integration into the Galician Colorectal Cancer Screening Programme. Previous studies have shown that GoodGut's test, by identifying a specific bacterial signature of colorectal cancer, can enhance the efficiency of disease diagnosis. 

Newborn Solutions, the medical devices startup member of CataloniaBio & HealthTech, announces that it has changed its brand. Its new name and identity: Kriba. The rebranding of the company represents a significant milestone in their journey, marking their commitment to innovation, health impact, and global accessibility in the field of non-invasive screening, detection, and monitoring of infections in serous fluids. “Months of planning, collaboration, and creative efforts have culminated in the birth of Kriba”, explain the company.

Wivi Vision, member of CataloniaBio & HealthTech, along with Bandora emerged as winners in the inaugural ‘pitch’ of the HearstLab 2023 initiative, which aims to promote female talent and women-led companies. 

Moreover, it is a field that is still full of uncertainties and, for this reason, CataloniaBio & HealthTech has brought together four experts from very different fields, such as business, health care providers, teaching and public agencies, to give their point of view and share their impressions, experiences and best practices in this area. The session was moderated by Alfons Nonell, CEO of DevsHealth and chair of the CataloniaBio & HealthTech Internal Digital Committee, who proposed the theme of the session.